T1	Participants 240 307	double-blind study in 173 newly diagnosed multiple myeloma patients
T2	Participants 430 465	The patients were randomly assigned
T3	Participants 799 830	All patients received melphalan
T4	Participants 1173 1189	Patients on EHDP
